Related Experiment Video
Updated: Jun 12, 2026
11:10
Hyperinsulinemic-euglycemic Clamps in Conscious, Unrestrained Mice
Published on: November 16, 2011
Insulin-resistance and benign prostatic hyperplasia: the connection
Ajit Vikram1, Gopabandhu Jena, Poduri Ramarao
1Department of Pharmacology and Toxicology, National Institute of Pharmaceutical Education and Research, S. A. S. Nagar, Mohali, Punjab, India. ajitvikram1602@yahoo.com
European Journal of Pharmacology
|June 18, 2010
Summary
Benign prostatic hyperplasia (BPH) is common in older men. Insulin resistance syndrome, marked by high insulin levels, may drive prostate growth and BPH development.
Area of Science:
- Urology
- Endocrinology
- Metabolic Syndrome
Background:
- Benign prostatic hyperplasia (BPH) is a prevalent condition in aging men, characterized by prostate gland enlargement.
- Prior research suggests a link between BPH and insulin resistance syndrome.
- Insulin resistance leads to hyperinsulinemia, which can promote prostate cell growth.
Purpose of the Study:
- To review the complex relationship between insulin resistance-associated factors and the development of BPH.
- To explore the molecular signaling pathways through which hyperinsulinemia may influence prostatic growth.
Main Methods:
- This is a review article, synthesizing existing research.
- It examines the individual and combined roles of obesity, dyslipidemia, sympathetic overactivity, and hyperinsulinemia in BPH pathogenesis.
Main Results:
- Insulin resistance syndrome encompasses multiple risk factors for BPH.
- Hyperinsulinemia, a key component, directly and indirectly impacts prostate molecular signaling.
- Each component of the syndrome is individually linked to increased BPH risk.
Conclusions:
- Insulin resistance syndrome and its components are significantly implicated in BPH development.
- Understanding these interrelationships is crucial for identifying novel therapeutic targets for BPH.
- Further research into the molecular mechanisms is warranted.
Related Concept Videos
01:24Type II Diabetes II: Pathophysiology
PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.
01:28Insulin: The Receptor and Signaling Pathways
Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but this inhibition is released...
01:26Type II Diabetes I: Introduction
Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, in which target tissues such as the liver, muscle, and adipose tissue respond poorly to insulin. It is also associated with inadequate compensatory insulin secretion, where pancreatic β-cells fail to produce sufficient insulin. Together, these abnormalities lead to persistent hyperglycemia.EtiologyT2DM develops through a complex interaction of genetic predisposition and environmental or...
01:26Type I Diabetes II: Pathophysiology
Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular uptake of...
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
01:19Psychoneuroimmunology: Diabetes and Cancer
Chronic stress has been linked to both the onset and progression of serious health conditions, including Type 2 diabetes and cancer. Type 2 diabetes, a widespread chronic illness, is closely associated with obesity and insulin resistance, both of which often worsen under stress. Studies indicate that men experiencing high levels of chronic stress face a 45% higher risk of developing diabetes compared to those with minimal stress. Stress triggers physiological responses that elevate blood...